Pernix Therapeutics Holdings (PTX) Shares are Up 6.07%

Pernix Therapeutics Holdings (PTX) : Traders are bullish on Pernix Therapeutics Holdings (PTX) as it has outperformed the S&P 500 by a wide margin of 26.47% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.14%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.07% in the last 1 week, and is up 30.71% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 10.62% and the 50-Day Moving Average is 17.09%. Pernix Therapeutics Holdings, Inc. has dropped 21.93% during the last 3-month period . Year-to-Date the stock performance stands at -80.15%.


Pernix Therapeutics Holdings (NASDAQ:PTX): stock turned positive on Friday. Though the stock opened at $0.556, the bulls momentum made the stock top out at $0.598 level for the day. The stock recorded a low of $0.5522 and closed the trading day at $0.5856, in the green by 3.10%. The total traded volume for the day was 2,002,036. The stock had closed at $0.568 in the previous days trading.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.